Vanguard Group Inc Avenue Therapeutics, Inc. Transaction History

Vanguard Group Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.24 - $6.6 $31,576 - $868,355	-131,569 Closed	0 $0
Q2 2022 Aug 12, 2022	SELL	$0.22 - $0.56 $70,638 - $179,807	-321,084 Reduced 70.93%	131,569 $36,000
Q3 2021 Nov 12, 2021	BUY	$1.48 - $2.65 $3,953 - $7,078	2,671 Added 0.59%	452,653 $675,000
Q2 2021 Aug 13, 2021	BUY	$2.41 - $7.11 $1.08 Million - $3.2 Million	449,982 New	449,982 $1.13 Million

Ticker ATXI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 4,127,720
Market Cap $14.1M
Description
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was in...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.